Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00002096
- Locations
- 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Ctr for Special Immunology, Irvine, California, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002001
- Locations
- 🇵🇷
San Juan Veterans Administration Med Ctr, San Juan, Puerto Rico
🇺🇸Georgetown Univ Med Ctr / Main Hosp 4, Washington, District of Columbia, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00000652
- Locations
- 🇺🇸
Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-04-30
- Target Recruit Count
- 10
- Registration Number
- NCT00001035
- Locations
- 🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸USC CRS, Los Angeles, California, United States
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 600
- Registration Number
- NCT00000991
- Locations
- 🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 240
- Registration Number
- NCT00000994
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 20
- Registration Number
- NCT00001003
- Locations
- 🇺🇸
SUNY - Stony Brook, Stony Brook, New York, United States
The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00000983
- Locations
- 🇺🇸
UCLA Med Ctr / Pediatric, Los Angeles, California, United States
🇺🇸Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.